Role of endocrine therapy in the neoadjuvant surgical setting
- 1 January 2004
- journal article
- research article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 11 (1) , 18S-23S
- https://doi.org/10.1007/bf02524791
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Neoadjuvant endocrine therapy of breast cancer: a surgical perspectiveEuropean Journal Of Cancer, 2002
- Endocrine and Clinical Endpoints of Exemestane as Neoadjuvant TherapyCancer Control, 2002
- Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized TrialJournal of Clinical Oncology, 2001
- Letrozole as Primary Medical Therapy for Locally Advanced and Large Operable Breast CancerBreast Cancer Research and Treatment, 2001
- Breast conservative surgery: is it appropriate for locally advanced breast cancer following downstaging by neoadjuvant chemotherapy. A pathological assessmentThe Breast, 1999
- Lessons from the use of aromatase inhibitors in the neoadjuvant setting.Endocrine-Related Cancer, 1999
- A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancerAnnals of Oncology, 1998
- Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.Journal of Clinical Oncology, 1998
- Conservation Surgery After Primary Chemotherapy in Large Carcinomas of the BreastAnnals of Surgery, 1995
- Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen onlyBritish Journal of Surgery, 1991